ELISA/assay

Isocitrate Dehydrogenase 1, Soluble (IDH1) ELISA Kit

MBS2022319

48-Strip-Wells

565 USD

ELISA Kit

Isocitrate Dehydrogenase 1, Soluble (IDH1) ELISA Kit

Isocitrate Dehydrogenase 1, Soluble (IDH1)

PICD; IDP; Oxalosuccinate decarboxylase; NADP(+)-specific ICDH; Cytosolic NADP-isocitrate dehydrogenase

isocitrate dehydrogenase 1 (NADP+), soluble, isoform CRA_b; Isocitrate dehydrogenase [NADP] cytoplasmic; isocitrate dehydrogenase [NADP] cytoplasmic; isocitrate dehydrogenase 1 (NADP+), soluble; Cytosolic NADP-isocitrate dehydrogenase; IDP; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase

IDH1

IDH1; IDH1; IDH; IDP; IDCD; IDPC; PICD; HEL-216; HEL-S-26; PICD; IDH

IDHC_HUMAN

Human

414

This assay has high sensitivity and excellent specificity for detection of Isocitrate Dehydrogenase 1, Soluble (IDH1). No significant cross-reactivity or interference between Isocitrate Dehydrogenase 1, Soluble (IDH1) and analogues was observed.

For unopened kit: All the reagents should be kept according to the labels on vials. The Standard, Detection Reagent A, Detection Reagent B and the 96-well strip plate should be stored at -20 degree C upon receipt while the others should be at 4 degree C. For opened kit: When the kit is opened, the remaining reagents still need to be stored according to the above storage condition. Besides, please return the unused wells to the foil pouch containing the desiccant pack, and reseal along entire edge of zip-seal. The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Samples: Serum, plasma, tissue homogenates, Cell lysates, cell culture supernates and other biological fluids. Assay Type: Sandwich. Detection Range: 3.13-200ng/mL. Sensitivity: Typically less than 1.39ng/mL.

Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Isocitrate Dehydrogenase 1, Soluble (IDH1) were tested 20 times on one plate, respectively. Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Isocitrate Dehydrogenase 1, Soluble (IDH1) were tested on 3 different plates, 8 replicates in each plate. CV(%) = SD/meanX100 . Intra-Assay: CV<10% . Inter-Assay: CV<12% . Assay Procedure Summary: 1. Prepare all reagents, samples and standards;. 2. Add 100uL standard or sample to each well. Incubate 2 hours at 37 degree C;. 3. Aspirate and add 100uL prepared Detection Reagent A. Incubate 1 hour at 37 degree C;. 4. Aspirate and wash 3 times;. 5. Add 100uL prepared Detection Reagent B. Incubate 30 minutes at 37 degree C;. 6. Aspirate and wash 5 times;. 7. Add 90uL Substrate Solution. Incubate 15-25 minutes at 37 degree C;. 8. Add 50uL Stop Solution. Read at 450nm immediately.

Principle of the Assay: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Isocitrate Dehydrogenase 1, Soluble (IDH1). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Isocitrate Dehydrogenase 1, Soluble (IDH1). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Isocitrate Dehydrogenase 1, Soluble (IDH1), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm 10nm. The concentration of Isocitrate Dehydrogenase 1, Soluble (IDH1) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

119590846

EAW70440.1

O75874

46,659 Da

2-Oxocarboxylic Acid Metabolism Pathway (714485); 2-Oxocarboxylic Acid Metabolism Pathway (717400); Abnormal Conversion Of 2-oxoglutarate To 2-hydroxyglutarate Pathway (771598); Biosynthesis Of Amino Acids Pathway (790012); Biosynthesis Of Amino Acids Pathway (795174); Carbon Metabolism Pathway (814926); Carbon Metabolism Pathway (817567); Central Carbon Metabolism In Cancer Pathway (1059538); Central Carbon Metabolism In Cancer Pathway (1084231); Citrate Cycle (TCA Cycle) Pathway (82927)

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Sep 2013]

IDH1: an oxidoreductase that catalyzes the third step of the TCA cycle: the oxidative decarboxylation of isocitrate, consuming NADP(+), and producing alpha-ketoglutarate (alpha-KG) and CO2. Alpha-KG is an activator the dioxygenases that hydroxylate the transcription factor HIF and lead to its degradation by VHL. Since HIF turns on oncogenic pathways, IDH1 has apparent tumor suppressor activity. Homo-dimerization is required for activity. Each subunit binds 1 magnesium or manganese ion. IDH1 is located in the cytosol and peroxisomes. Somatic mutations affecting arginine 132 (R132) are found in 80% of grade II?III gliomas and secondary glioblastomas in humans, and cause disease in a tissue-specific fashion. Only a single copy of the gene has been found to be mutated in tumours. Mutations of R132 to H, C, S, G, V, or L have been reported to be neomorphic, abolishing the conversion of isocitrate to alpha-KG. Instead, alpha-KG is converted to R(-)-2-hydroxyglutarate (2HG). Elevated levels of 2HG correlate with an elevated risk of malignant brain tumors. Neomorphic mutations in IDH1 and IDH2 convert alpha-KG to 2-hydroxyglutarate (2-HG) occur in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML). Protein type: Carbohydrate Metabolism - citrate (TCA) cycle; EC 1.1.1.42; Other Amino Acids Metabolism - glutathione; Oxidoreductase. Chromosomal Location of Human Ortholog: 2q33.3. Cellular Component: peroxisomal matrix; mitochondrion; cytoplasm; peroxisome; cytosol. Molecular Function: protein homodimerization activity; magnesium ion binding; isocitrate dehydrogenase (NADP+) activity; NADP binding; NAD binding; receptor binding. Biological Process: glyoxylate cycle; NADPH regeneration; isocitrate metabolic process; glutathione metabolic process; tricarboxylic acid cycle; response to steroid hormone stimulus; response to oxidative stress; cellular lipid metabolic process; female gonad development; 2-oxoglutarate metabolic process. Disease: Glioma Susceptibility 1

48-Strip-Wells

565 USD

96-Strip-Wells

765

5x96-Strip-Wells

2975

10x96-Strip-Wells

5340